



HAL
open science

Demographics and Baseline Characteristics of Patients with Idiopathic Pulmonary Fibrosis (IPF) in a Real-World Setting: Results of 847 Patients Enrolled in the Radico-ILD Cohort in France

V Cottin, S Jouneau, B Crestani, H Nunes, L Wemeau, P Bonniaud, D Israël-Biet, M Reynaud-Gaubert, J Dalphin, J Naccache, et al.

► To cite this version:

V Cottin, S Jouneau, B Crestani, H Nunes, L Wemeau, et al.. Demographics and Baseline Characteristics of Patients with Idiopathic Pulmonary Fibrosis (IPF) in a Real-World Setting: Results of 847 Patients Enrolled in the Radico-ILD Cohort in France. American Thoracic Society, May 2020, Virtuel, France. 201 (A3349). inserm-04056757

HAL Id: inserm-04056757

<https://inserm.hal.science/inserm-04056757v1>

Submitted on 3 Apr 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Demographics and Baseline Characteristics of Patients with Idiopathic Pulmonary Fibrosis (IPF) in a Real-World Setting: Results of 847 Patients Enrolled in the Radico-ILD Cohort in France

V. Cottin¹, S. Jouneau², B. Crestani³, H. Nunes⁴, L. Wemeau⁵, P. Bonniaud⁶, D. Israël-Blet⁷, M. Reynaud-Gaubert⁸, J. Dalphin⁹, J. Naccache¹⁰, S. Marchand-Adam¹¹, S. Quetant¹², D. Montani¹³, S. Hirschi¹⁴, M. Chevereau¹⁵, I. Dufaure-Garé¹⁵, A. F. Clement¹⁶, RaDiCo-ILD; ¹Louis Pradel Hosp, Univ of Lyon, Lyon, France, ²Pneumologie, CHU de Rennes, Rennes, France, ³Service de Pneumologie, Hopital Bichat, Paris, France, ⁴Avicenne hospital, Bobigny, France, ⁵University of Lille, Lille, France, ⁶University of Dijon, Dijon, France, ⁷University Paris HEGP, Paris, France, ⁸University of Marseille, Marseille, France, ⁹Université Franche Comté, Besançon, France, ¹⁰University Paris Tenon, Lyon, France, ¹¹University of Tours, Tours, France, ¹²University of Grenoble, Grenoble, France, ¹³Service de Pneumologie, Centre de reference de l'Hypertension Pulmonaire Sévère, Hopital de Bicetre, Le Kremlin Bicêtre, France, ¹⁴University of Strasbourg, Strasbourg, France, ¹⁵RaDiCo, Inserm, Paris, France, ¹⁶Trousseau Hosp, Paris 75012, France.

Corresponding author's email: vincent.cottin@chu-lyon.fr

Rationale: Idiopathic pulmonary fibrosis (IPF) is a rare condition and few epidemiological data are available in France. This specific research project aims to describe characteristics of treated IPF patients and the impact of antifibrotic treatments in terms of morbidity and mortality in the French real-life setting. **Methods:** The French RaDiCo (Rare Disease Cohort)-ILD (idiopathic Interstitial Lung Diseases) registry is an ongoing observational study initiated in June 2017, with a sub-analysis of IPF patients. This longitudinal long-term cohort includes pediatric and adult patients with ILD and is supported by the national network of reference and competence centers for rare pulmonary diseases. IPF was diagnosed using international ATS/ERS 2011 criteria with a diagnosis of IPF or working diagnosis of IPF by multidisciplinary discussion. Here, we present the baseline data of IPF patients. **Results:** Between June 15th 2017 and September 4th 2019, 1246 ILD patients were enrolled in the RaDiCo-ILD registry from 18 centers, including 847 with IPF (68%). IPF patients were mostly male (82.7%), with a mean age of 72.5 ± 9 years at inclusion and a mean BMI of 26.8 ± 4.3; 44.6 % of IPF patients included were incident cases, with a median length between diagnosis and inclusion of 8.9 months (Q1=0.9 and Q3=26.4); 25.3% had a biopsy. The mean FVC at IPF diagnosis was 73.4 ± 25.0 % of predicted value (n=561), and the mean DLCO at IPF diagnosis was 39.6 ± 18.2 % predicted value (n=498). Among patients with available information on anti-fibrotic treatment, 347 had been treated (at least one dose) with nintedanib, and 312 with pirfenidone; among patients treated with antifibrotics, 113 were treated with both treatments sequentially. **Conclusions:** The RaDiCo-ILD registry provides accurate real-world data on the demographics of patients with IPF in France. It will generate a long-term follow-up and will be an invaluable tool to describe the natural history and progression of patients with IPF in real-life conditions.

This abstract is funded by: ANR from France; institutional support from Boehringer Ingelheim and Roche

Am J Respir Crit Care Med 2020;201:A3349
Internet address: www.atsjournals.org

Online Abstracts Issue